Scientific Publications

CLINUVEL has conducted over 15 trials of SCENESSE® (afamelanotide 16mg) involving over 900 patients, published research from which can be purchased online.

Below is a selection of published research on SCENESSE®. These links direct you to sites outside of the control of CLINUVEL which are not produced or endorsed by CLINUVEL.

Langendonk J, Balwani M, Anderson K et al (2015). “Afamelanotide for Erythropoietic Protoporphria”. New Eng J Med. 373(1):48-59.
Biolcati G, Marchesini E, Sorge F et al (2015). “Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria.” Br J Dermatol. 172(6):1601-1612. E-Pub Dec 13, 2014. Available online:
Minder E & Schneider-Yin X (2014). “Afamelanotide (CUV1647) in dermal phototoxicity of erythropoietic protoporphyria”. Expert Rev Clin Pharmacol. 7(6).
Lim HW, Grimes PE, Agbai O, et al (2014). “Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo”. JAMA Dermatol. E-Pub Sept 17.
Biolcati G et al (2013). “Efficacy of the melanocortin analogue Nle4-D-Phe7-α-melanocyte-stimulating hormone in the treatment of patients with Hailey–Hailey disease.” Clin Exp Dermatol. E-Pub 25 Oct.
Fabrikant J, Touloei K & Brown SM, (2013). “A Review and Update on Melanocyte Stimulating Hormone Therapy: Afamelanotide”. J Drugs Dermatol. 12(7):775-779.
Bohm M, Ehrchen J & Luger TA, (2012). “Beneficial effects of the melanocortin analogue Nle(4) -d-Phe(7) -α-MSH in acne vulgaris.” JEADV. E-Pub July 27.
Haylett AK, Nie Z, Brownrigg M, Taylor R, E Rhodes L, (2010). “Systemic photoprotection in solar urticaria with α-melanocyte stimulating hormone analogue [Nle(4) -D-Phe(7) ]-α-MSH.” Br J Dermatol. 164(2):407-14.
Minder, EI (2010). “Afamelanotide”. Drugs of the Future. 35(5): 365.
Harms JH, Lautenschlager S, Minder CE, Minder EI, (2009). “Mitigating photosensitivity of erythropoietic protoporphyria patients by an agonistic analog of alpha-melanocyte stimulating hormone.” Photochem Photobiol 85(6):1434-9.
Harms, J et al., (2009), ‘An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria’, New Eng J Med. 360(3):306-307.
Barnetson R, et al, (2006). “[Nle4-D-Phe7]-alpha-Melanocyte-Stimulating Hormone Significantly Increased Pigmentation and Decreased UV Damage in Fair-Skinned Caucasian Volunteers.” Journal of Investigative Dermatology 126, 1869-1878.
Hadley ME, Dorr RT, (2006). “Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization.” Peptides 27(4):921-30. E-Pub Jan 18.
Fitzgerald LM, Fryer JL, Dwyer T, Humphrey SM, (2006). “Effect of [Nle(4), D-Phe(7)]-alpha-MSH, on melanin synthesis in humans with MC1R variant alleles.” Peptides 27(2):388-94. E-Pub 2005 Nov 15.
Dorr RT, et al, (2000). “Increased eumelanin expression and tanning is induced by a superpotent melanotropin [Nle4-D-Phe7]-alpha-MSH in humans.” Photochem Photobiol 72(4):526-32.
Levine N, et al (1999). “Effects of a potent synthetic melanotropin, Nle4-D-Phe7-α-MSH (Melanotan-I) on tanning: a dose-ranging study.” Journal of Dermatological Treatment 10(2):127-32.

Over 200 articles have been published on afamelanotide (chemical name [Nle4, D-Phe7]α-MSH or NDP-MSH).